Skip to main content
Premium Trial:

Request an Annual Quote

Abcam Acquires Applied StemCell Gene Editing Platform, Oncology Product Line

NEW YORK — Abcam said on Thursday that it has acquired the gene editing platform and oncology product portfolio of Applied StemCell for the research and diagnostic markets.

According to Abcam, the deal includes Applied StemCell's portfolio of cell lines and its AccuRef reference materials product line, which is used to mimic cancer mutations and create biologically relevant quality control and reference standards for over 40 cancer genes.

Abcam said that it is working with Applied StemCell to ensure continuity of service and project delivery as ownership of the assets is transferred between the companies. UK-based Abcam added that it intends to use its acquisition to build out a discovery engine for developing novel edited cell lines and support its knockout validation initiative for antibody quality control.

Financial terms of the deal were not disclosed.

"We are excited to … [bring] in one of the most widely deployed and technically successful cell engineering platforms into the Abcam family," Cheri Walker, senior vice president of corporate development at Abcam, said in a statement. "The cell line market is in the early stages of development as a research tool, where the ready provision of more choice, with the right gene targets in the right cell lines, will allow the market to rapidly expand."

Abcam acquired the live cell line and lysates portfolio of EdiGene in July after dropping its bid for gene editing and gene modulation technologies firm Horizon Discovery.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.